IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1076-1100 out of 1337.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

Public Release: 6-Jan-2016
Science Translational Medicine
Early trial shows injectable agent illuminates cancer during surgery
Doctors at the Duke University School of Medicine have tested a new injectable agent that causes cancer cells in a tumor to fluoresce, potentially increasing a surgeon's ability to locate and remove all of a cancerous tumor on the first attempt. The imaging technology was developed through collaboration with scientists at Duke, the Massachusetts Institute of Technology and Lumicell Inc.
American Society of Clinical Oncology, National Institutes of Health, NIH/National Cancer Institute, NIH/National Center for Advancing Translational Science, Duke Comprehensive Cancer Center

Contact: Samiha Khanna
samiha.khanna@duke.edu
919-419-5069
Duke University Medical Center

Public Release: 6-Jan-2016
Contemporary Clinical Trials Communications
New open access journal highlights methods and clinical trial results
The first issue of Elsevier's new open access journal Contemporary Clinical Trials Communications features a new method to make cancer clinical trials more effective, a better way of determining whether a trial was successful and a dashboard that helps patients enroll in trials.

Contact: Jason Awerdick
j.awerdick@elsevier.com
212-633-3103
Elsevier

Public Release: 6-Jan-2016
The Lancet
Winship multiple myeloma study in The Lancet
Winship multiple myeloma expert Sagar Lonial, M.D., played a key role in the testing of daratumumab (trade name Darzalex), which received accelerated approval from the US FDA in November 2015.
Janssen Biotech

Contact: Catherine Williams
catherine.s.williams@emory.edu
404-778-5848
Emory Health Sciences

Public Release: 6-Jan-2016
The BMJ
Cancer screening has never been shown to 'save lives,' argue experts
Cancer screening has never been shown to 'save lives' as advocates claim, argue experts in The BMJ today.

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ

Public Release: 6-Jan-2016
Cell Metabolism
Scientists root out the 'bad seeds' of liver cancer
Researchers have found the 'bad seeds' of liver cancer and believe they could one day reprogram them to remain responsive to cancer treatment, a new USC study has found. The key to disrupting chemo-resistant stem cells that become liver tumors from multiplying is to target the stem cell marker NANOG, said Keigo Machida, senior author.
National Institutes of Health, Animal Core, Morphology Core, and Pilot Project Program, Non-Parenchymal Liver Cell Core, Research Scholar Grant, American Cancer Society

Contact: Zen Vuong
zvuong@usc.edu
213-300-1381
University of Southern California

Public Release: 6-Jan-2016
Human Molecular Genetics
Cancer drug shows promise for treating Duchenne muscular dystrophy
A drug commonly used to treat leukemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
Muscular Dystrophy UK, Medical Research Council, Duchenne Parent Project NL

Contact: Beck Lockwood
beck@campuspr.co.uk
University of Sheffield

Public Release: 5-Jan-2016
JAMA
Twin study estimates familial risks of 23 different cancers
A large new study of twins has found that having a twin sibling diagnosed with cancer poses an excess risk for the other twin to develop any form of cancer.
Ellison Foundation to Harvard T.H. Chan School of Public Health, Nordic Cancer Union

Contact: Todd Datz
tdatz@hsph.harvard.edu
617-432-8413
Harvard T.H. Chan School of Public Health

Public Release: 5-Jan-2016
JAMA
Long-term follow-up of risk of cancer among twins
In a long-term follow-up study among approximately 200,000 Nordic twin individuals, there was an increased cancer risk in twins whose co-twin was diagnosed with cancer, with an increased risk for cancer overall and for specific types of cancer, including prostate, melanoma, breast, ovary, and uterus, according to a study in the Jan. 5 issue of JAMA.

Contact: Lorelei A. Mucci
lmucci@hsph.harvard.edu
The JAMA Network Journals

Public Release: 5-Jan-2016
Nature Communications
CNIO finds a possible new pharmacological target for one of the most important and elusive oncogenes
MYC is altered in more than half of human cancers, and it is often associated with very aggressive tumors. Researchers have identified a second gene, called BPTF, that has an important role in the chain of molecular events that allow MYC to function, therefore revealing itself as a possible new therapeutic target.

Contact: Vanessa Pombo
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncológicas (CNIO)

Public Release: 5-Jan-2016
Menopause
DHEA improves vaginal discomfort after menopause
A new phase III trial with positive results is taking intravaginal DHEA a step closer to governmental approval. The formulation could provide women who cannot or do not wish to use intravaginal estrogen with an effective vaginal alternative for easing vaginal symptoms and pain with sex after menopause. The trial results were published online today in Menopause, the journal of The North American Menopause Society.
EndoCeutics

Contact: Eileen Petridis
epetridis@fallscommunications.com
216-696-0229
The North American Menopause Society (NAMS)

Public Release: 5-Jan-2016
International Journal of Radiation Oncology, Biology, Physics
Radiation an important addition to treatment for pancreatic cancer surgery candidates
Radiation therapy was associated with a lower risk of cancer recurrence in pancreatic cancer surgery patients, making it, like chemotherapy, an important addition to treatment, Mayo Clinic research found.

Contact: Sharon Theimer
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 5-Jan-2016
ecancermedicalscience
Association for Cancer Physicians releases cancer patient strategy for UK
The Association for Cancer Physicians, which represents and supports medical oncologists in the UK, has published a new strategy for improving cancer patient services and outcomes.

Contact: Audrey Nailor
audrey@ecancer.org
44-011-740-33098
ecancermedicalscience

Public Release: 5-Jan-2016
Proceedings of the National Academy of Sciences
Novel RNA delivery system may treat incurable blood cancers
Mantle Cell Lymphoma is considered the most aggressive known blood cancer, and available therapies are scarce. A new study by Tel Aviv University researchers offers tangible hope of curing the currently incurable cancer -- and others like it.

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University

Public Release: 4-Jan-2016
Oncogene
Gene thought to suppress cancer may actually promote spread of colorectal cancer
A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer, University of Missouri School of Medicine researchers have found. It is a finding that may lay the foundation for new colorectal cancer treatments.
National Institutes of Health, Veterans Affairs Merit Award, University of Missouri Research Board Award, University of Missouri School of Medicine Bridge

Contact: Derek Thompson
thompsonder@health.missouri.edu
573-882-3323
University of Missouri-Columbia

Public Release: 4-Jan-2016
Journal of Pain and Symptom Management
Racial bias may be conveyed by doctors' body language
Physicians give less compassionate nonverbal cues when treating seriously ill black patients compared with their white counterparts, a small University of Pittsburgh School of Medicine trial revealed. It is the first to look at such interactions in a time-pressured, end-of-life situation.
American Cancer Society, National Cancer Institute

Contact: Allison Hydzik
HydzikAM@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences

Public Release: 4-Jan-2016
Journal of the Federation of American Societies for Experimental Biology
New paste prevents scarring caused by radiation therapy for cancer
An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy.
National Institutes of Health, Laura and Isaac Perlmutter Cancer Center

Contact: Greg Williams
gregory.williams@nyumc.org
212-404-3533
New York University

Public Release: 4-Jan-2016
Journal of Urology
Prostate cancer surveillance criteria may not be accurate for African American men
A new study published in The Journal of Urology revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs.

Contact: Linda Gruner
jumedia@elsevier.com
212-633-3923
Elsevier Health Sciences

Public Release: 4-Jan-2016
BJU International
Prostate surgery patients may have unrealistic expectations concerning their recovery
Patients who have undergone radical prostatectomy often have largely unrealistic expectations with regard to their postoperative sexual function, new research shows.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 4-Jan-2016
Annals of Neurology
Medical research influenced by training 'genealogy'
By analyzing peer-reviewed scientific papers that examined the effectiveness of a surgical procedure, researchers at University of California, San Diego School of Medicine provide evidence suggesting that the conclusions of these studies appear to be influenced by the authors' mentors and medical training.
UC San Diego/Czech Duck Research Fellowship in Neurosurgery

Contact: Heather Buschman
hbuschman@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 4-Jan-2016
Journal of Hunger & Environmental Nutrition
Miriam Hospital, R.I. Community Food Bank study dispels belief healthy diets are costly
Research conducted by The Miriam Hospital and The Rhode Island Community Food Bank demonstrated that -- contrary to popular belief -- healthy diets rich in fruits and vegetables are affordable.

Contact: Elena Falcone-Relvas
efalconerelvas@lifespan.org
401-639-7172
Lifespan

Public Release: 4-Jan-2016
Journal of Thoracic Oncology
Improving access to clinical trials when biopsies are required
The requirement for tumor tissue specimens and associated analyses in order to participate in clinical trials appears to be a significant barrier to clinical trial enrollment and may delay treatment. Potential solutions to reducing or eliminating these barriers include routine tissue banking at diagnosis, easing use of available diagnostic samples, development of less invasive tests, faster turnaround time at central laboratories or allowing for local testing and more resources for timely tissue collection.

Contact: Jeff Wolf
Jeff.Wolf@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer

Public Release: 3-Jan-2016
Nucleic Acids Research
Biggest database for cancer drug discovery goes 3-D
The world's largest database for cancer drug discovery has been revolutionized by adding 3-D structures of faulty proteins and maps of cancer's communication networks, according to Cancer Research UK-funded research published in Nucleic Acid Research today (Monday).
Cancer Research UK

Contact: Emma Rigby
emma.rigby@cancer.org.uk
020-346-98300
Cancer Research UK

Public Release: 1-Jan-2016
Clinical Cancer Research
Three hits to fight lung cancer
A new study in mice has shown that cancers with KRAS-related gene mutations might benefit from a triple therapy with two experimental drugs plus radiation therapy.

Contact: Colleen Cordaro
colleen.cordaro@jefferson.edu
215-955-2238
Thomas Jefferson University

Public Release: 1-Jan-2016
Cancer Research
Sugar in western diets increases risk for breast cancer tumors and metastasis
The high amounts of dietary sugar in the typical western diet may increase the risk of breast cancer and metastasis to the lungs, according to a study at The University of Texas MD Anderson Cancer Center.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 31-Dec-2015
Cell Reports
Sylvester researchers describe role of STING protein in development of colorectal cancer
A new study published today by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine (Sylvester) reports on a key finding about the immune system's response to tumor development following studies on colorectal cancer. This is the first detailed examination of how the stimulator of interferon genes (STING) signaling pathway may play an important role in alerting the immune system to cellular transformation.

Contact: Patrick Bartosch
patrick.bartosch@med.miami.edu
201-469-6408
University of Miami Miller School of Medicine

Showing releases 1076-1100 out of 1337.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

  Search News Releases

     

 

EurekAlert!